NZ747404A - Pharmaceutical combinations for the treatment of cancer - Google Patents

Pharmaceutical combinations for the treatment of cancer

Info

Publication number
NZ747404A
NZ747404A NZ747404A NZ74740417A NZ747404A NZ 747404 A NZ747404 A NZ 747404A NZ 747404 A NZ747404 A NZ 747404A NZ 74740417 A NZ74740417 A NZ 74740417A NZ 747404 A NZ747404 A NZ 747404A
Authority
NZ
New Zealand
Prior art keywords
treatment
cancer
pharmaceutical combinations
inhibitor
combination therapies
Prior art date
Application number
NZ747404A
Other languages
English (en)
Inventor
Richard Klinghoffer
Joyoti Dey
Original Assignee
Presage Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Presage Biosciences Inc filed Critical Presage Biosciences Inc
Priority to NZ757763A priority Critical patent/NZ757763B2/en
Publication of NZ747404A publication Critical patent/NZ747404A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ747404A 2016-03-28 2017-03-28 Pharmaceutical combinations for the treatment of cancer NZ747404A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ757763A NZ757763B2 (en) 2017-03-28 Pharmaceutical combinations for the treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662314356P 2016-03-28 2016-03-28
PCT/US2017/024618 WO2017172826A1 (en) 2016-03-28 2017-03-28 Pharmaceutical combinations for the treatment of cancer

Publications (1)

Publication Number Publication Date
NZ747404A true NZ747404A (en) 2020-03-27

Family

ID=59966407

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ747404A NZ747404A (en) 2016-03-28 2017-03-28 Pharmaceutical combinations for the treatment of cancer

Country Status (13)

Country Link
US (5) US11135198B2 (enExample)
EP (1) EP3436002B1 (enExample)
JP (3) JP7114478B2 (enExample)
KR (5) KR102545392B1 (enExample)
CN (1) CN109689047B (enExample)
AU (4) AU2017241914B2 (enExample)
CA (2) CA3018932C (enExample)
IL (3) IL312398A (enExample)
MX (3) MX2018011666A (enExample)
NZ (1) NZ747404A (enExample)
RU (1) RU2726367C2 (enExample)
WO (1) WO2017172826A1 (enExample)
ZA (2) ZA201806819B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2840687C (en) 2011-07-01 2020-04-28 Dana-Farber Cancer Institute, Inc. Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
JP6879740B2 (ja) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
IL312398A (en) * 2016-03-28 2024-06-01 Presage Biosciences Inc Pharmaceutical combinations for cancer treatment
EP3703755B1 (en) * 2017-10-31 2024-07-31 Eisai R&D Management Co., Ltd. Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors for use in the treatment of cancer
CN108186642B (zh) * 2018-01-11 2019-11-08 广西师范大学 一种协同起作用治疗肺癌的药物组合物
CN108261414B (zh) * 2018-01-11 2019-09-06 广西师范大学 一种治疗肺癌的药物组合物
WO2020036995A1 (en) * 2018-08-14 2020-02-20 Mei Pharma, Inc. Combination therapy
WO2020092615A1 (en) * 2018-11-01 2020-05-07 Oregon Health & Science University Treatments for venetoclax-resistant and venetoclax-sensitive acute myeloid leukemia
CA3136599A1 (en) 2019-04-11 2020-10-15 Mei Pharma, Inc. Voruciclib poly morphs and methods of making and using thereof
AU2020362194A1 (en) * 2019-10-08 2022-05-19 Dana-Farber Cancer Institute, Inc. A pyrazolopyrimidine derivative as a HCK inhibitor for use in therapy, in particular MYD88 mutated diseases
EP4106760A4 (en) * 2020-05-07 2024-03-27 Recurium IP Holdings, LLC COMBINATIONS
CN117043159A (zh) * 2020-11-19 2023-11-10 梅制药公司 Kras突变型癌症的治疗
IL302925A (en) * 2020-11-19 2023-07-01 Mei Pharma Inc Treatment of kras mutant cancers
CN113018357A (zh) * 2021-02-08 2021-06-25 湖南农业大学 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途
JP2024516097A (ja) * 2021-04-10 2024-04-12 メイ ファーマ，インク． ボルシクリブ（ｖｏｒｕｃｉｃｌｉｂ）投与レジメンおよびこれを含む治療方法
WO2024239512A1 (zh) * 2023-05-22 2024-11-28 劲方医药科技(上海)有限公司 药物组合及其在治疗癌症中的用途
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2219867A1 (en) * 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US7271193B2 (en) 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
PT1768966E (pt) 2004-06-17 2012-05-23 Infinity Discovery Inc Compostos e métodos para inibir a interacção de proteínas bcl com parceiros de ligação
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
CN101175738B (zh) 2005-05-12 2010-10-27 雅培制药有限公司 细胞凋亡促进剂
MX2007014783A (es) 2005-05-24 2008-02-19 Abbott Lab Activadores de apoptosis.
WO2007129062A1 (en) * 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
US8563596B2 (en) 2006-06-21 2013-10-22 Piramal Enterprises Limited Enantiomerically pure compounds for the treatment of proliferative disorders
JP5688288B2 (ja) * 2007-05-15 2015-03-25 ピラマル エンタープライジーズ リミテッド がんの処置のための相乗的な医薬の組合せ
US9259399B2 (en) * 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
CN102325531B (zh) 2008-12-19 2014-04-02 健泰科生物技术公司 化合物和使用方法
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
BR112013012313A2 (pt) * 2010-11-19 2019-09-24 Piramal Entpr Ltd combinação farmacêutica de paclitaxel e um inibidor de cdk
TW201300105A (zh) * 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
ES2959198T3 (es) * 2012-07-24 2024-02-21 Avalyn Pharma Inc Compuestos análogos de pirfenidona y piridona en aerosol
US9241941B2 (en) * 2012-09-20 2016-01-26 Memorial Sloan-Kettering Cancer Center Methods for treatment of lymphomas with mutations in cell cycle genes
JP6347793B2 (ja) 2013-01-16 2018-06-27 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン Ｂｃｌ−２／Ｂｃｌ−ｘＬ阻害薬およびそれを使用した治療方法
CN105164117B (zh) * 2013-03-14 2019-02-01 欧尼斯治疗公司 二肽和三肽环氧酮蛋白酶抑制剂
US20150044288A1 (en) * 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US10314842B2 (en) 2013-12-02 2019-06-11 Cornell University Methods for treating B cell proliferative disorders
WO2015130585A1 (en) 2014-02-28 2015-09-03 Merck Sharp & Dohme Corp. Method for treating cancer
WO2015181737A1 (en) 2014-05-28 2015-12-03 Piramal Enterprises Limited Pharmaceutical combination for the treatment of cancer
HRP20211813T1 (hr) * 2014-08-11 2022-03-04 Acerta Pharma B.V. Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
US9637488B2 (en) * 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
IL312398A (en) 2016-03-28 2024-06-01 Presage Biosciences Inc Pharmaceutical combinations for cancer treatment

Also Published As

Publication number Publication date
KR102599512B1 (ko) 2023-11-07
RU2020121147A (ru) 2021-11-03
RU2726367C2 (ru) 2020-07-13
AU2021273532B2 (en) 2024-02-01
IL295472A (en) 2022-10-01
NZ757763A (en) 2025-07-25
JP2024038227A (ja) 2024-03-19
US20200383948A1 (en) 2020-12-10
KR20230156443A (ko) 2023-11-14
CA3018932A1 (en) 2017-10-05
US11135198B2 (en) 2021-10-05
MX2022002318A (es) 2022-04-06
WO2017172826A1 (en) 2017-10-05
KR20230021155A (ko) 2023-02-13
KR20210088016A (ko) 2021-07-13
ZA202107579B (en) 2025-03-26
KR20190039878A (ko) 2019-04-16
KR102275758B1 (ko) 2021-07-12
IL295472B1 (en) 2024-06-01
IL261824B2 (en) 2023-02-01
MX2018011666A (es) 2019-07-08
CN109689047B (zh) 2025-03-21
JP7416872B2 (ja) 2024-01-17
IL261824A (en) 2018-10-31
AU2020201247A1 (en) 2020-03-12
RU2018137687A3 (enExample) 2020-04-29
AU2024200194A1 (en) 2024-02-01
US20220023261A1 (en) 2022-01-27
KR20230093360A (ko) 2023-06-27
IL261824B (en) 2022-10-01
US12121508B2 (en) 2024-10-22
CA3103604A1 (en) 2017-10-05
JP2022141916A (ja) 2022-09-29
EP3436002A1 (en) 2019-02-06
RU2018137687A (ru) 2020-04-29
KR102494039B1 (ko) 2023-01-30
AU2017241914B2 (en) 2020-02-27
IL295472B2 (en) 2024-10-01
JP7114478B2 (ja) 2022-08-08
US20210283104A1 (en) 2021-09-16
AU2017241914A1 (en) 2018-11-08
CA3103604C (en) 2023-09-26
IL312398A (en) 2024-06-01
CA3018932C (en) 2021-10-26
KR102545392B1 (ko) 2023-06-20
ZA201806819B (en) 2022-03-30
EP3436002B1 (en) 2025-11-05
US20190275004A1 (en) 2019-09-12
CN109689047A (zh) 2019-04-26
MX2022011750A (es) 2022-10-18
AU2021273532A1 (en) 2021-12-16
US12171744B2 (en) 2024-12-24
US20250221961A1 (en) 2025-07-10
EP3436002A4 (en) 2019-12-04
JP2019514854A (ja) 2019-06-06
AU2020201247B2 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
ZA202107579B (en) Pharmaceutical combinations for the treatment of cancer
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
TN2019000210A1 (en) Antitumoral compounds
GEP20207161B (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
CA2983481A1 (en) Janus kinase inhibitor
PH12016502354A1 (en) Pharmaceutical composition
NZ779654A (en) Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
MY176235A (en) Compounds that inhibit mcl-1 protein
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
NZ629456A (en) Methods for treating cancer using tor kinase inhibitor combination therapy
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MX2022008175A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
WO2016133903A3 (en) Combination therapy for cancer treatment
MX379621B (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
MX393711B (es) Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12017501879A1 (en) Methods for treating cancer
MX2020005659A (es) Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia.
MY202127A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PH12017501882A1 (en) Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
MX2019003603A (es) Terapia de combinacion con un inhibidor de mek, un inhibidor del eje pd-1 y un taxano.
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210331

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2023 BY COMPUTER PACKAGES INC

Effective date: 20220330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2024 BY COMPUTER PACKAGES INC

Effective date: 20230330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2025 BY COMPUTER PACKAGES INC

Effective date: 20240330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 MAR 2026 BY SOUTHERN CROSS INTELLECTUAL PROPERTY LIMITED

Effective date: 20250925